top of page
Curated from the NCI drug list with >100 malignant hem, onc, and supportive care drugs of relevance added by my personal review of major guidelines such as NCCN, ASH, etc..
FDA approved Malig. Hem / Onc drugs through Jan. 2024 I Next Update 5/2024 I Benign Hem. Drugs in process
Your content has been submitted
An error occurred. Try again later
Generic Drug Name | Brand Name | Drug Classification |
|---|---|---|
Abatacept | Orencia | Immunosuppressant, T-cell Costimulation Inhibitor |
Abemaciclib | Verzenio | Small Molecule Kinase Inhibitors, Cyclin-Dependent Kinase Inhibitors |
Abiraterone Acetate | Zytiga; Yonsa | Hormonal Therapies, Androgens and Anti-Androgens |
Acalabrutinib | Calquence | Small Molecule Kinase Inhibitors, Bruton's Tyrosine Kinase (BTK) Inhibitors |
Acitretin | Soriatane | Vitamin A derivative (retinoid) |
Adagrasib | Krazati | Small Molecule GTPase Inhibitors, Kirsten rat sarcoma virus (KRAS) |
Ado-Trastuzumab Emtansine (T-Dm1) | Kadcyla | Antibody-Drug Conjugate |
Afatinib | Gilotrif | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Aldesleukin (Interleukin-2) | Proleukin | Recombinant Proteins, Hormones, and Enzymes |
Alectinib Hydrochloride | Alecensa | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Alemtuzumab | Campath | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Alitretinoin | Panretin | Vitamin A derivative (retinoid) |
Alpelisib | Piqray, Vijoice | Small Molecule Kinase Inhibitors, Phosphoinositide-3 Kinase (Pi3K) Inhibitors |
Amifostine | Ethyol | Antidote to Chemotherapy Toxicity |
Amivantamab-vmjw | Rybrevant | Monoclonal Antibodies |
Anakinra | Kineret | Monoclonal Antibodies |
Anastrozole | Arimidex | Hormonal Therapies, Aromatase Inhibitors |
Andexanet Alfa | Andexxa | other |
Antithymocyte Globulin Equine | Atgam | other |
Antithymocyte Globulin Rabbit | Thymoglobulin | other |
Apalutamide | Erleada | Hormonal Therapies, Androgens and Anti-Androgens |
Apixaban | Elliquis | anticoagulant |
Aprepitant | Emend (Fosaprepitant Also Branded As Emend) | Antiemetic |
Arsenic Trioxide | Trisenox | Arsenicals |
Asciminib | Scemblix | Small Molecule Kinase Inhibitors, BCR-ABL1 Inhibitors |
Atezolizumab | Tecentriq | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Avapritinib | Ayvakit | Small Molecule Kinase Inhibitors, Kit (CD117), Platelet Derived Growth Factor Receptor Alpha (PDGFRA), and Colony Stimulating Factor 1 Receptor (CSFR1) |
Avatrombopag Maleate | Doptelet | Small Molecule TPO Receptor agonists |
Avelumab | Bavencio | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Axicabtagene Ciloleucel (Axi-Cel) | Yescarta | Immune Effector Cell Therapy |
Axitinib | Inlyta | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Azacitidine | Onureg; Vidaza | Epigenetic Regulation Modifiers |
Bcg (Bacillus Calmette-Guerin) | Tice | Antineoplastic agent, other |
Belantamab Mafodotin-blmf | Blenrep | Antibody-Drug Conjugate |
Belinostat | Beleodaq | Epigenetic Regulation Modifiers |
Belumosudil | Rezurock | Small Molecule Kinase Inhibitors, Other |
Belzutifan | Welireg | small molecule targeted therapy |
Bendamustine Hydrochloride | Treanda | Cytotoxic Chemotherapy, Alkylating |
Betibeglogene Autotemcel | Zynteglo | Gene Therapy |
Bevacizumab | Avastin; Alymsys; Zirabev | Monoclonal Antibodies |
Bevacizumab-Awwb | Mvasi | Monoclonal Antibodies |
Bexarotene | Targretin | Vitamin A derivative (retinoid) |
Bicalutamide | Bicalutamide | Hormonal Therapies, Androgens and Anti-Androgens |
Binimetinib | Mektovi | Small Molecule Kinase Inhibitors, Mitogen-Activated Protein Kinase (MEK) Inhibitors |
Bleomycin | Blenoxane | Antineoplastic agent, other |
Blinatumomab | Blincyto | Bispecific T Cell Engager |
Bortezomib | Velcade | Proteasome Inhibitors |
Bosutinib Monohydrate | Bosulif | Small Molecule Kinase Inhibitors, BCR-ABL1 Inhibitors |
Brentuximab Vedotin | Adcetris | Antibody-Drug Conjugate |
Brexucabtagene Autoleucel (Brexu-Cel) | Tecartus | Immune Effector Cell Therapy |
Brigatinib | Alunbrig | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Buprenorphine | Subutex | Opioid Receptor Agonists and Antagonists |
Bupropion Hydrochloride | Zyban | Dopamine/Norepinephrine Reuptake Inhibitor; Smoking Cessation Aid |
Busulfan | Busulfex, Myleran | Cytotoxic Chemotherapy, Alkylating |
Butalbital, Acetaminophen, Caffeine, And Codeine Phosphate | Fioricet With Codeine | Opioid Agonists and Antagonists |
Cabazitaxel | Jevtana | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Cabozantinib | Cabometyx | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Cabozantinib | Cometriq | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Calaspargase Pegol | Asparlas | Antineoplastic agent, other |
Capecitabine | Xeloda | Cytotoxic Chemotherapy, Antimetabolites |
Capivasertib | Truqap | Small Molecule Kinase Inhibitors, Other |
Caplacizumab | Cablivi | Monoclonal Antibodies |
Capmatinib | Tabrecta | Small Molecule Kinase Inhibitors, Other |
Carboplatin | Paraplatin | Cytotoxic Chemotherapy, Alkylating |
Carfilzomib | Kyprolis | Proteasome Inhibitors |
Carmustine | Bcnu | Cytotoxic Chemotherapy, Alkylating |
Carmustine Implant | Gliadel Wafer | Cytotoxic Chemotherapy, Alkylating |
Cemiplimab-Rwlc | Libtayo | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Ceritinib | Zykadia | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Cetuximab | Erbitux | Monoclonal Antibodies |
Chlorambucil | Leukeran | Cytotoxic Chemotherapy, Alkylating |
Ciltacabtagene Autoleucel (Cilta-Cel) | Carvykti | Immune Effector Cell Therapy |
Cisplatin | Cisplatin | Cytotoxic Chemotherapy, Alkylating |
Citalopram Hydrobromide | Celexa | Selective Serotonin Reuptake Inhibitor (SSRI) |
Cladribine | Cladribine | Cytotoxic Chemotherapy, Antimetabolites |
Clofarabine | Clofarabine | Cytotoxic Chemotherapy, Antimetabolites |
Cobimetinib | Cotellic | Small Molecule Kinase Inhibitors, Mitogen-Activated Protein Kinase (MEK) Inhibitors |
Copanlisib | Aliqopa | Small Molecule Kinase Inhibitors, Phosphoinositide-3 Kinase (Pi3K) Inhibitors |
Crizanlizumab | Akadveo | Sickle Cell Disease Therapeutics, not otherwise specified |
Crizotinib | Xalkori | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Cyclophosphamide | Cytoxan | Cytotoxic Chemotherapy, Alkylating |
Cyclosporine | Neoral | Immunosuppressant, Calcineurin Inhibitor |
Cytarabine | Cytarabine | Cytotoxic Chemotherapy, Antimetabolites |
Dabigatran Etexilate Mesylate | Pradaxa | anticoagulant |
Dabrafenib | Tafinlar | Small Molecule Kinase Inhibitors, B-Raf (BRAF) Inhibitors |
Dacarbazine | Dacarbazine | Cytotoxic Chemotherapy, Alkylating |
Dacomitinib | Vizimpro | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Dactinomycin | Dactinomycin | Cytotoxic Chemotherapy, DNA-Damaging Agents |
Dalteparin Sodium | Fragmin | anticoagulant |
Daratumumab (Intravenous) | Darzalex | Monoclonal Antibodies |
Daratumumab And Hyaluronidase-Fihj (Subcutaneous) | Darzalex Faspro | Monoclonal Antibodies |
Darbepoetin Alfa | Aranesp | Recombinant Proteins, Hormones, and Enzymes |
Darolutamide | Nubeqa | Hormonal Therapies, Androgens and Anti-Androgens |
Dasatinib | Sprycel | Small Molecule Kinase Inhibitors, BCR-ABL1 Inhibitors |
Daunorubicin Hydrochloride | Rubidomycin | Cytotoxic Chemotherapy, Anthracyclines, Topoisomerase II inhibitor |
Decitabine | Decitabine | Epigenetic Regulation Modifiers |
Decitabine And Cedazuridine | Inquovi | Epigenetic Regulation Modifiers |
Degarelix | Firmagon | Hormonal Therapies, Gonadotropin-Releasing Hormone Analogues |
Denileukin Diftitox | Ontak | Recombinant Proteins, Hormones, and Enzymes |
Denosumab | Prolia; Xgeva | Bone Metabolism Modifiers: bisphosphonates and RANKL inhibitors |
Dexamethasone | Decadron | Corticosteroids |
Dexrazoxane Hydrochloride | Totect; Zinecard | Antidote to Chemotherapy Toxicity |
Dinutuximab | Unituxin | Monoclonal Antibodies |
Docetaxel Anhydrous | Taxotere | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Dostarlimab-Gxly | Jemperli | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Doxorubicin Hydrochloride | Adriamycin | Cytotoxic Chemotherapy, Anthracyclines, Topoisomerase II inhibitor |
Duloxetine Hydrochloride | Cymbalta | Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) |
Durvalumab | Imfinzi | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Duvelisib | Copiktra | Small Molecule Kinase Inhibitors, Phosphoinositide-3 Kinase (Pi3K) Inhibitors |
Eculizumab | Soliris | Monoclonal Antibodies |
Edoxaban Tosylate | Savaysa | anticoagulant |
Elacestrant | Orserdu | Hormonal Therapies, Estrogens and Selective Estrogen Response Modifiers |
Elotuzumab | Empliciti | Monoclonal Antibodies |
Eltrombopag Olamine | Promacta | Small Molecule TPO Receptor agonists |
Emapalumab | Gamifant | Monoclonal Antibodies |
Enasidenib Mesylate | Idhifa | Small Molecule Kinase Inhibitors, Other |
Encorafenib | Braftovi | Small Molecule Kinase Inhibitors, B-Raf (BRAF) Inhibitors |
Enfortumab Vedotin-ejfv | Padcev | Antibody-Drug Conjugate |
Enoxaparin Sodium | Enoxaparin Sodium | anticoagulant |
Entrectinib | Rozlytrek | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Enzalutamide | Xtandi | Hormonal Therapies, Androgens and Anti-Androgens |
Epirubicin Hydrochloride | Ellence | Cytotoxic Chemotherapy, Anthracyclines, Topoisomerase II inhibitor |
Epoetin Alfa | Procrit; Retacrit | Recombinant Proteins, Hormones, and Enzymes |
Epoetin Alfa | Epogen | Recombinant Proteins, Hormones, and Enzymes |
Erdafitinib | Balversa | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Eribulin Mesylate | Halaven | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Erlotinib Hydrochloride | Tarceva | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Erwinia Asparaginase | Erwinaze | Antineoplastic agent, other |
Erwinia Asparaginase (Recombinant) | Rylaze | Antineoplastic agent, other |
Escitalopram Oxalate | Lexapro | Selective Serotonin Reuptake Inhibitor (SSRI) |
Etoposide | Etopophos | Cytotoxic Chemotherapy, Topoisomerase II Inhibitors |
Etranacogene Dezaparvovec-Drlb | Hemgenix | Gene Therapy |
Everolimus | Everolimus | Immunosuppresant, mTOR inhibitors |
Everolimus | Afinitor | Small Molecule Kinase Inhibitors, Mammalian Target Of Rapamycin (MTOR) Inhibitors |
Exagamglogene Autotemcel | Casgevy | Gene Therapy |
Exemestane | Aromasin | Hormonal Therapies, Aromatase Inhibitors |
Fam-Trastuzumab Deruxtecan-Nxki (T-Dxd) | Enhertu | Antibody-Drug Conjugate |
Fedratinib Hydrochloride | Inrebic | Small Molecule Kinase Inhibitors, Janus Kinase (Jak) Inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors |
Fentanyl Transdermal System | Duragesic | Opioid Receptor Agonists and Antagonists |
Filgrastim | Neupogen; Granix; Nivestym; Zarxio | Recombinant Proteins, Hormones, and Enzymes |
Filgrastim | Releuko | Recombinant Proteins, Hormones, and Enzymes |
Fludarabine Phosphate | Fludarabine Phosphate | Cytotoxic Chemotherapy, Antimetabolites |
Fluorouracil | Fluorouracil | Cytotoxic Chemotherapy, Antimetabolites |
Fluorouracil (Topical) | Tolak | Cytotoxic Chemotherapy, Antimetabolites |
Fluoxetine Hydrochloride | Prozac | Selective Serotonin Reuptake Inhibitor (SSRI) |
Flutamide | Eulexin | Hormonal Therapies, Androgens and Anti-Androgens |
Fondaparinux Sodium | Fondaparinux Sodium | anticoagulant |
Fosaprepitant | Emend (Aprepitant Also Branded As Emend) | Antiemetic |
Fostamatinib Disodium | Tavalisse | Small Molecule Kinase Inhibitors, Other |
Fulvestrant | Fulvestrant | Hormonal Therapies, Estrogens and Selective Estrogen Response Modifiers |
Futibatinib | Lytgobi | Small Molecule Kinase Inhibitors, Other |
Gabapentin | Neurontin | other |
Gefitinib | Iressa | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Gemcitabine Hydrochloride | Gemzar; Infugem | Cytotoxic Chemotherapy, Antimetabolites |
Gemtuzumab Ozogamicin | Mylotarg | Antibody-Drug Conjugate |
Gilteritinib | Xospata | Small Molecule Kinase Inhibitors, Janus Kinase (Jak) Inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors |
Glasdegib | Daurismo | small molecule targeted therapy |
Glofitamab-Gxbm | Columvi | Bispecific T Cell Engager |
Glucarpidase | Voraxaze | Antidote to Chemotherapy Toxicity |
Goserelin | Zoladex | Hormonal Therapies, Gonadotropin-Releasing Hormone Analogues |
Granisetron Hydrochloride | Kytril; Sancuso | Antiemetic |
A
Anchor 2
Generic Drug Name | Brand Name | Drug Classification |
|---|---|---|
Heparin Sodium | Heparin Sodium | anticoagulant |
Hydrocortisone | Solu-Cortef | Corticosteroids |
Hydromorphone Hydrochloride | Dilaudid | Opioid Receptor Agonists and Antagonists |
Hydroxyurea | Hydrea | Sickle Cell Disease Therapeutics, not otherwise specified |
Ibritumomab Tiuxetan (With In-111 And Y-90) | Zevalin | Radioactive Therapeutic and Diagnostic Agents |
Ibrutinib | Imbruvica | Small Molecule Kinase Inhibitors, Bruton's Tyrosine Kinase (BTK) Inhibitors |
Idarubicin Hydrochloride | Idamycin Pfs | Cytotoxic Chemotherapy, Anthracyclines, Topoisomerase II inhibitor |
Idarucizumab | Praxbind | other |
Idecabtagene Vicleucel (Ide-Cel) | Abecma | Immune Effector Cell Therapy |
Idelalisib | Zydelig | Small Molecule Kinase Inhibitors, Phosphoinositide-3 Kinase (Pi3K) Inhibitors |
Ifosfamide | Ifex | Cytotoxic Chemotherapy, Alkylating |
Imatinib Mesylate | Gleevec | Small Molecule Kinase Inhibitors, BCR-ABL1 Inhibitors |
Imiquimod | Aldara; Zyclara | other |
Infigratinib Phosphate | Truseltiq | Small Molecule Kinase Inhibitors, Other |
Inotuzumab Ozogamicin | Besponsa | Antibody-Drug Conjugate |
Interferon-Gamma-1B | Actimmune | Recombinant Proteins, Hormones, and Enzymes |
Iobenguane I 131 | Azedra | Radioactive Therapeutic and Diagnostic Agents |
Ipilimumab | Yervoy | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Irinotecan Hydrochloride | Irinotecan Hydrochloride 100 Mg/5 Ml | Cytotoxic Chemotherapy, Topoisomerase I Inhibitors |
Isatuximab-Irfc | Sarclisa | Monoclonal Antibodies |
Ivosidenib | Tibsovo | Small Molecule Targeted Therapy, Isocitrate Dehydrogenase (IDH) Inhibitors |
Ixabepilone | Ixempra | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Ixazomib | Ninlaro | Proteasome Inhibitors |
L - Glutamine | Endari | Sickle Cell Disease Therapeutics, not otherwise specified |
Lanreotide Acetate | Somatuline Depot | Recombinant Proteins, Hormones, and Enzymes |
Lapatinib | Tykerb | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Larotrectinib | Vitrakvi | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Lenalidomide | Revlimid | Immunomodulatory Drugs (IMiDs) |
Lenvatinib | Lenvima | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Letrozole | Letrozole | Hormonal Therapies, Aromatase Inhibitors |
Letrozole And Ribociclib | Kisqali Femara Co-Pack | Small Molecule Kinase Inhibitors, Cyclin-Dependent Kinase Inhibitors |
Leucovorin Calcium | Fusilev | other |
Leuprolide Acetate | Eligard; Lupron Depot | Hormonal Therapies, Gonadotropin-Releasing Hormone Analogues |
Leuprolide Mesylate | Camcevi | Hormonal Therapies, Gonadotropin-Releasing Hormone Analogues |
Levonorgestrel And Ethinyl Estradiol | Iclevia | Hormonal Therapies, Contraceptives |
Liposomal Daunorubicin And Cytarabine | Vyxeos | other |
Liposomal Doxorubicin | Doxil | Cytotoxic Chemotherapy, Anthracyclines, Topoisomerase II inhibitor |
Liposomal Irinotecan | Onivyde | Cytotoxic Chemotherapy, Topoisomerase I Inhibitors |
Lisocabtagene Maraleucel (Liso-Cel) | Breyanzi | Immune Effector Cell Therapy |
Lomustine | Gleostine | Cytotoxic Chemotherapy, Alkylating |
Loncastuximab Tesirine-lpyl | Zynlonta | Antibody-Drug Conjugate |
Lorlatinib | Lorbrena | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Lovotibeglogene Autotemcel | Lyfgenia | Gene Therapy |
Lurbinectedin | Zepzelca | Cytotoxic Chemotherapy, Alkylating |
Luspatercept-Aamt | Reblozyl | Recombinant Proteins, Hormones, and Enzymes |
Lusutrombopag | Mulpleta | Small Molecule TPO Receptor agonists |
Lutetium Lu 177 Dotatate | Lutathera | Radioactive Therapeutic and Diagnostic Agents |
Lutetium Lu 177 Vipivotide Tetraxetan | Pluvicto | Radioactive Therapeutic and Diagnostic Agents |
Margetuximab-Cmkb | Margenza | Monoclonal Antibodies |
Mechlorethamine Hydrochloride | Valchlor | Cytotoxic Chemotherapy, Alkylating |
Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | Hormonal Therapies, Contraceptives |
Megestrol Acetate | Megestrol Acetate | Hormonal Therapies, Progestins and Antiprogestins |
Melphalan Hydrochloride | Evomela; Alkeran; Hepzato | Cytotoxic Chemotherapy, Alkylating |
Mercaptopurine | Purinethol; Purixan | Cytotoxic Chemotherapy, Antimetabolites |
Mesna | Mesnex | Antidote to Chemotherapy Toxicity |
Methadone Hydrochloride | Dolophine | Opioid Receptor Agonists and Antagonists |
Methotrexate | Trexall; Xatmep | Cytotoxic Chemotherapy, Antimetabolites |
Methylnaltrexone Bromide | Relistor | Opioid Agonists and Antagonists |
Methylphenidate Hydrochloride | Ritalin | CNS Stimulant |
Midostaurin | Rydapt | Small Molecule Kinase Inhibitors, Janus Kinase (Jak) Inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors |
Mirtazapine | Remeron | Alpha-2-Antagonist; Appetite Stimulant |
Mirvetuximab Soravtansine-gynx | Elahere | Antibody-Drug Conjugate |
Mitomycin | Jelmyto | Cytotoxic Chemotherapy, Alkylating |
Mitotane | Lysodren | other |
Mitoxantrone | Mitoxantrone | Cytotoxic Chemotherapy, Anthracyclines, Topoisomerase II inhibitor |
Mogamulizumab-Kpkc | Poteligeo | Monoclonal Antibodies |
Momelotinib Dihydrochloride Monohydrate | Ojjaara | Small Molecule Kinase Inhibitors, Janus Kinase (Jak) Inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors |
Morphine Sulfate | Morphine Sulfate | Opioid Receptor Agonists and Antagonists |
Mosunetuzumab-Axgb | Lunsumio | Bispecific T Cell Engager |
Moxetumomab Pasudotox-tdfk | Lumoxiti | Antibody-Drug Conjugate |
Mycophenylate Mofetil | Cellcept | Immunosuppressant |
Nadofaragene Firaden | Adstiladrin | Gene Therapy |
Nadofaragene Firadenovec-Vncg | Adstiladrin | Gene Therapy |
Naxitamab-Gqgk | Danyelza | Monoclonal Antibodies |
Necitumumab | Portrazza | Monoclonal Antibodies |
Nelarabine | Arranon | Cytotoxic Chemotherapy, Antimetabolites |
Neratinib | Nerlynx | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Netupitant And Palonosetron Hydrochloride | Akynzeo | Antiemetic |
Nilotinib | Tasigna | Small Molecule Kinase Inhibitors, BCR-ABL1 Inhibitors |
Nilutamide | Nilandron | Hormonal Therapies, Androgens and Anti-Androgens |
Niraparib | Zejula | Poly(ADP-ribose) polymerase (PARP) inhibitors |
Niraparib And Abiraterone | Akeega | Poly(ADP-ribose) polymerase (PARP) inhibitors |
Nirogacestat Hydrobromide | Ogsiveo | small molecule targeted therapy |
Nivolumab | Opdivo | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Nivolumab And Relatlimab-Rmbw | Opdualag | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
H
Anchor 1
O
Z
Generic Drug Name | Brand Name | Drug Classification |
|---|---|---|
Obinutuzumab | Gazyva | Monoclonal Antibodies |
Octreotide Acetate | Sandostatin | Recombinant Proteins, Hormones, and Enzymes |
Ofatumumab | Kesimpta; Arzerra | Monoclonal Antibodies |
Olaparib | Lynparza | Poly(ADP-ribose) polymerase (PARP) inhibitors |
Olutasidenib | Rezlidhia | Small Molecule Targeted Therapy, Isocitrate Dehydrogenase (IDH) Inhibitors |
Omacetaxine Mepesuccinate | Synribo | Small Molecule Kinase Inhibitors, BCR-ABL1 Inhibitors |
Omidubicel-Only | Omisirge | Gene Therapy |
Ondansetron Hydrochloride | Zofran | Antiemetic |
Osimertinib | Tagrisso | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Oxaliplatin | Oxaliplatin | Cytotoxic Chemotherapy, Alkylating |
Oxycodone Hydrochloride | Oxecta | Opioid Receptor Agonists and Antagonists |
Paclitaxel (Albumin-Bound) | Paclitaxel Protein-Bound Particles For Injectable Suspension (Albumin-Bound) | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Pacritinib | Vonjo | Small Molecule Kinase Inhibitors, Janus Kinase (Jak) Inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors |
Palbociclib | Ibrance | Small Molecule Kinase Inhibitors, Cyclin-Dependent Kinase Inhibitors |
Palifermin | Kepivance | Recombinant Proteins, Hormones, and Enzymes |
Palonosetron Hydrochloride | Aloxi | Antiemetic |
Pamidronate Disodium | Aredia | Bone Metabolism Modifiers: bisphosphonates and RANKL inhibitors |
Panitumumab | Vectibix | Monoclonal Antibodies |
Paroxetine Hydrochloride Hemihydrate | Paxil | Selective Serotonin Reuptake Inhibitor (SSRI) |
Pazopanib Hydrochloride | Votrient | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Pegaspargase | Oncaspar | Antineoplastic agent, other |
Pegaspargase | Oncaspar | Recombinant Proteins, Hormones, and Enzymes |
Pegfilgrastim | Neulasta; Nyvepria; Undencyca; Ziextenzo | Recombinant Proteins, Hormones, and Enzymes |
Peginterferon Alfa-2A | Pegasys | Recombinant Proteins, Hormones, and Enzymes |
Pembrolizumab | Keytruda | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Pemetrexed Disodium | Alimta; Pemfexy | Cytotoxic Chemotherapy, Antimetabolites |
Pemigatinib | Pemazyre | Small Molecule Kinase Inhibitors, Other |
Pentostatin | Pentostatin | Cytotoxic Chemotherapy, Antimetabolites |
Pertuzumab | Perjeta | Monoclonal Antibodies |
Pertuzumab And Trastuzumab And Hyaluronidase-zzxf | Phesgo | Antibody-Drug Conjugate |
Pexidartinib | Turalio | Small Molecule Kinase Inhibitors, Other |
Pirtobrutinib | Jaypirca | Small Molecule Kinase Inhibitors, Bruton's Tyrosine Kinase (BTK) Inhibitors |
Plerixafor | Mozobil | other |
Polatuzumab Vedotin-piiq | Polivy | Antibody-Drug Conjugate |
Pomalidomide | Pomalyst | Immunomodulatory Drugs (IMiDs) |
Ponatinib Hydrochloride | Iclusig | Small Molecule Kinase Inhibitors, BCR-ABL1 Inhibitors |
Pralatrexate | Folotyn | Cytotoxic Chemotherapy, Antimetabolites |
Pralsetinib | Gavreto | Small Molecule Kinase Inhibitors, Other |
Prednisone | Prednisone | Corticosteroids |
Pregabalin | Lyrica | other |
Procarbazine Hydrochloride | Matulane | Cytotoxic Chemotherapy, Alkylating |
Prochlorperazine Maleate | Compazine | Antiemetic |
Promethazine Hydrochloride | Phenergan | Antiemetic |
Propranolol Hydrochloride | Hemangeol | other |
Quizartinib Dihydrochloride | Vanflyta | Small Molecule Kinase Inhibitors, Janus Kinase (Jak) Inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors |
Radium 223 Dichloride | Xofigo | Radioactive Therapeutic and Diagnostic Agents |
Raloxifene Hydrochloride | Evista | Hormonal Therapies, Estrogens and Selective Estrogen Response Modifiers |
Ramucirumab | Cyramza | Monoclonal Antibodies |
Rasburicase | Elitek | Recombinant Proteins, Hormones, and Enzymes |
Ravulizumab | Ultomiris | Monoclonal Antibodies |
Regorafenib | Stivarga | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Relugolix | Orgovyx | Hormonal Therapies, Gonadotropin-Releasing Hormone Analogues |
Repotrectinib | Augtyro | Small Molecule Kinase Inhibitors, Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET) Growth Factor Inhibitors, Rearranged During Transfection (RET), Proto-Oncogene Ros1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) Inhibitors |
Retifanlimab-Dlwr | Zynyz | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Ribociclib | Kisqali | Small Molecule Kinase Inhibitors, Cyclin-Dependent Kinase Inhibitors |
Ripretinib | Qinlock | Small Molecule Kinase Inhibitors, Kit (CD117), Platelet Derived Growth Factor Receptor Alpha (PDGFRA), and Colony Stimulating Factor 1 Receptor (CSFR1) |
Rituximab | Rituxan; Riabni; Ruxience; Truxima | Monoclonal Antibodies |
Rituximab And Hyaluronidase | Rituxan Hycela | Monoclonal Antibodies |
Rivaroxaban | Xarelto | anticoagulant |
Rolapitant | Varubi | Antiemetic |
Romidepsin | Istodax | Epigenetic Regulation Modifiers |
Romiplostim | Nplate | Recombinant Proteins, Hormones, and Enzymes |
Ropeginterferon Alfa-2B-Njft | Besremi; Intron A | Recombinant Proteins, Hormones, and Enzymes |
Rucaparib | Rubraca | Poly(ADP-ribose) polymerase (PARP) inhibitors |
Ruxolitinib | Jakifi | Small Molecule Kinase Inhibitors, Janus Kinase (Jak) Inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors |
Sacituzumab Govitecan-hziy | Trodelvy | Antibody-Drug Conjugate |
Selinexor | Xpovio | other |
Selpercatinib | Retevmo | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Selumetinib | Koselugo | Small Molecule Kinase Inhibitors, Mitogen-Activated Protein Kinase (MEK) Inhibitors |
Sertraline Hydrochloride | Zoloft | Selective Serotonin Reuptake Inhibitor (SSRI) |
Siltuximab | Sylvant | Monoclonal Antibodies |
Sipuleucel-T | Provenge | Immune Effector Cell Therapy |
Sirolimus | Fyarro | Small Molecule Kinase Inhibitors, Mammalian Target Of Rapamycin (MTOR) Inhibitors |
Sirolimus | Rapamune | Small Molecule Kinase Inhibitors, Mammalian Target Of Rapamycin (MTOR) Inhibitors |
Sonidegib | Odomzo | small molecule targeted therapy |
Sorafenib | Nexavar | Small Molecule Kinase Inhibitors, Other |
Sotorasib | Lumakras | Small Molecule GTPase Inhibitors, Kirsten rat sarcoma virus (KRAS) |
Streptozocin | Zanosar | Cytotoxic Chemotherapy, Alkylating |
Sunitinib Malate | Sutent | Small Molecule Kinase Inhibitors, Kit (CD117), Platelet Derived Growth Factor Receptor Alpha (PDGFRA), and Colony Stimulating Factor 1 Receptor (CSFR1) |
Tacrolimus (Alias: Fk506) | Prograf | Immunosuppressant, Calcineurin Inhibitor |
Tafasitamab-Cxix | Monjuvi | Monoclonal Antibodies |
Tagraxofusp-erzs | Elzonris | Antibody-Drug Conjugate |
Talazoparib | Talzenna | Poly(ADP-ribose) polymerase (PARP) inhibitors |
Talimogene Laherparepvec | Imlygic | Tumor vaccines and viral-based immunotherapeutics |
Talimogene Laherparepvec | Imlygic | Gene Therapy |
Talquetamab-Tgvs | Talvey | Bispecific T Cell Engager |
Tamoxifen Citrate | Soltamox | Hormonal Therapies, Estrogens and Selective Estrogen Response Modifiers |
Tazarotene (Cream) | Tazorac | Vitamin A derivative (retinoid) |
Tazemetostat | Tazverik | Epigenetic Regulation Modifiers |
Tebentafusp-Tebn | Kimmtrak | Bispecific T Cell Engager |
Teclistamab-Cqyv | Tecvayli | Bispecific T Cell Engager |
Temozolomide | Temodar | Cytotoxic Chemotherapy, Alkylating |
Temsirolimus | Torisel | Small Molecule Kinase Inhibitors, Mammalian Target Of Rapamycin (MTOR) Inhibitors |
Tepotinib Hydrochloride | Tepmetko | Small Molecule Kinase Inhibitors, Other |
Thalidomide | Thalomid | Immunomodulatory Drugs (IMiDs) |
Thioguanine | Tabloid | Cytotoxic Chemotherapy, Antimetabolites |
Thiotepa | Tepadina | Cytotoxic Chemotherapy, Alkylating |
Tisagenlecleucel (Tisa-Cel) | Kymriah | Immune Effector Cell Therapy |
Tisotumab Vedotintftv | Tivdak | Antibody-Drug Conjugate |
Tivozanib | Fotivda | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Tocilizumab | Actemra | Monoclonal Antibodies |
Topotecan | Hycamtin | Cytotoxic Chemotherapy, Topoisomerase I Inhibitors |
Toremifene | Fareston | Hormonal Therapies, Estrogens and Selective Estrogen Response Modifiers |
Toripalimab-Tpzi | Loqtorzi | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Trabectedin | Yondelis | Cytotoxic Chemotherapy, Alkylating |
Tramadol Hydrochloride | Ultram | Opioid Receptor Agonists and Antagonists |
Trametinib | Mekinist | Small Molecule Kinase Inhibitors, Mitogen-Activated Protein Kinase (MEK) Inhibitors |
Trastuzumab | Herceptin; Herzuma; Kanjinti; Ogivri; Ontruzant; Trazimera | Monoclonal Antibodies |
Trastuzumab And Hyaluronidase-Oysk | Herceptin Hylecta | Monoclonal Antibodies |
Trazodone Hydrochloride | Trazodone Hydrochloride | Serotonin Reuptake Inhibitor/Antagonist |
Tremelimumab-Actl | Imjudo | Monoclonal Antibodies, Immune Checkpoint Inhibitors |
Tretinoin (Atra) | Vesanoid | Vitamin A derivative (retinoid) |
Trifluridine And Tipiracil | Lonsurf | Cytotoxic Chemotherapy, Antimetabolites |
Triptorelin Pamoate | Trelstar | Hormonal Therapies, Gonadotropin-Releasing Hormone Analogues |
Tucatinib | Tukysa | Small Molecule Kinase Inhibitors, Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (oral) Inhibitors |
Uridine Triacetate | Vistogard | Antidote to Chemotherapy Toxicity |
Valoctocogene Roxaparvovec-Rvox | Roctavian | Gene Therapy |
Valrubicin Intravesical Solution | Valstar | Cytotoxic Chemotherapy, Anthracyclines, Topoisomerase II inhibitor |
Vandetanib | Caprelsa | Small Molecule Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR)/Multi-Targeted Inhibitors |
Varenicline | Chantix | Smoking Cessation Aid |
Vemurafenib | Zelboraf | Small Molecule Kinase Inhibitors, B-Raf (BRAF) Inhibitors |
Venetoclax | Venclexta | BCL-2 (B-cell lymphoma-2) inhibitor |
Venlafaxine | Effexor Xr | Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) |
Vinblastine Sulfate | Vinblastine Sulfate | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Vincristine Sulfate | Vincristine Sulfate | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Vinorelbine | Navelbine | Cytotoxic Chemotherapy, Anti-Tubulin Agents |
Vismodegib | Erivedge | small molecule targeted therapy |
Vorinostat | Zolinza | Epigenetic Regulation Modifiers |
Voxelotor | Oxybryta | Sickle Cell Disease Therapeutics, not otherwise specified |
Warfarin Sodium | Warfarin Sodium | anticoagulant |
Zanubrutinib | Brukinsa | Small Molecule Kinase Inhibitors, Bruton's Tyrosine Kinase (BTK) Inhibitors |
Ziv-Aflibercept | Zaltrap | Recombinant Proteins, Hormones, and Enzymes |
Zoledronic Acid | Zometa | Bone Metabolism Modifiers: bisphosphonates and RANKL inhibitors |
Anchor 3
Anchor 4
bottom of page